Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Gene |
RCV000435144 | SCV000536485 | uncertain significance | not provided | 2022-05-04 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
| Prevention |
RCV004529579 | SCV004109592 | uncertain significance | ATRX-related disorder | 2023-05-26 | criteria provided, single submitter | clinical testing | The ATRX c.3655G>A variant is predicted to result in the amino acid substitution p.Gly1219Arg. To our knowledge, this variant has not been reported in the literature or in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
| Ambry Genetics | RCV004965461 | SCV005536103 | uncertain significance | Inborn genetic diseases | 2024-11-15 | criteria provided, single submitter | clinical testing | The c.3655G>A (p.G1219R) alteration is located in exon 9 (coding exon 9) of the ATRX gene. This alteration results from a G to A substitution at nucleotide position 3655, causing the glycine (G) at amino acid position 1219 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
| Natera, |
RCV001828456 | SCV002087294 | uncertain significance | Alpha thalassemia-X-linked intellectual disability syndrome | 2021-08-02 | no assertion criteria provided | clinical testing |